TW202506185A - 抗TGF-β抗體及其用途 - Google Patents

抗TGF-β抗體及其用途 Download PDF

Info

Publication number
TW202506185A
TW202506185A TW113140547A TW113140547A TW202506185A TW 202506185 A TW202506185 A TW 202506185A TW 113140547 A TW113140547 A TW 113140547A TW 113140547 A TW113140547 A TW 113140547A TW 202506185 A TW202506185 A TW 202506185A
Authority
TW
Taiwan
Prior art keywords
tgf
cells
antibody
seq
cancer
Prior art date
Application number
TW113140547A
Other languages
English (en)
Chinese (zh)
Inventor
蓋瑞 夏皮羅
凱文 布勞爾
派翠克 芬恩
理查 格雷戈里
拉歐 柯都里
鋒 劉
納塔利婭 瑪爾科娃
帕明德 米高
傑克 波拉德
華偉 邱
約阿希姆 泰哈柏
克里斯多福 溫特
翠琤 俞
Original Assignee
法商賽諾菲公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 法商賽諾菲公司 filed Critical 法商賽諾菲公司
Publication of TW202506185A publication Critical patent/TW202506185A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW113140547A 2017-01-20 2018-01-18 抗TGF-β抗體及其用途 TW202506185A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762448800P 2017-01-20 2017-01-20
EP17305061.8 2017-01-20
US62/448,800 2017-01-20
EP17305061 2017-01-20

Publications (1)

Publication Number Publication Date
TW202506185A true TW202506185A (zh) 2025-02-16

Family

ID=61656071

Family Applications (3)

Application Number Title Priority Date Filing Date
TW113140547A TW202506185A (zh) 2017-01-20 2018-01-18 抗TGF-β抗體及其用途
TW111145565A TWI856437B (zh) 2017-01-20 2018-01-18 抗TGF-β抗體及其用途
TW107101789A TWI787230B (zh) 2017-01-20 2018-01-18 抗ＴＧＦ-β抗體及其用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW111145565A TWI856437B (zh) 2017-01-20 2018-01-18 抗TGF-β抗體及其用途
TW107101789A TWI787230B (zh) 2017-01-20 2018-01-18 抗ＴＧＦ-β抗體及其用途

Country Status (21)

Country Link
US (4) US10766955B2 (enExample)
JP (3) JP7213186B2 (enExample)
CN (2) CN117417939A (enExample)
AU (2) AU2018209391B2 (enExample)
BR (1) BR112019014787A2 (enExample)
CA (1) CA3050845A1 (enExample)
CL (1) CL2019002011A1 (enExample)
CO (1) CO2019008946A2 (enExample)
CR (1) CR20190375A (enExample)
DO (1) DOP2019000191A (enExample)
EC (1) ECSP19059553A (enExample)
IL (3) IL268112B2 (enExample)
MA (1) MA47311A (enExample)
MX (2) MX2019008551A (enExample)
MY (1) MY200751A (enExample)
PE (1) PE20200734A1 (enExample)
PH (1) PH12019501635A1 (enExample)
SG (1) SG11201906660TA (enExample)
TW (3) TW202506185A (enExample)
UY (1) UY37575A (enExample)
ZA (1) ZA201904494B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR110755A1 (es) 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
US20210155708A1 (en) * 2018-07-10 2021-05-27 Sanofi Combination therapies against cancer targeting cd38 and tgf-beta
CN120535649A (zh) 2018-08-30 2025-08-26 免疫生物公司 单链嵌合多肽和其用途
NZ772550A (en) 2018-08-30 2025-08-29 Immunitybio Inc Multi-chain chimeric polypeptides and uses thereof
KR20210117271A (ko) * 2018-12-21 2021-09-28 노쓰웨스턴유니버시티 근막 손상 예방 및 치료를 위한 아넥신의 사용근각 손상 예방 및 치료를 위한 아넥신의 사용
EP3739588A1 (en) * 2019-05-13 2020-11-18 Koninklijke Philips N.V. Assessment of multiple signaling pathway activity score in airway epithelial cells to predict airway epithelial abnormality and airway cancer risk
KR20220035394A (ko) 2019-06-21 2022-03-22 에이치씨더블유 바이올로직스, 인크. 다중-사슬 키메라 폴리펩티드 및 이의 용도
WO2021163298A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
AU2021220870A1 (en) 2020-02-11 2022-08-04 Immunitybio, Inc. Methods of treating age-related and inflammatory diseases
KR20220140535A (ko) 2020-02-11 2022-10-18 에이치씨더블유 바이올로직스, 인크. 크로마토그래피 수지 및 이의 용도
CN113563473A (zh) 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
US20220119513A1 (en) * 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
CN112940119B (zh) * 2021-04-26 2022-05-20 北京芳渟阳生生物科技有限公司 一种单克隆抗体及其与间充质干细胞外泌体的联合应用
WO2022266510A1 (en) * 2021-06-18 2022-12-22 Genzyme Corporation Anti-tgf-beta antibody formulations and their use
CA3227318A1 (en) 2021-08-11 2023-02-16 HCW Biologics, Inc. Multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases
CN115707716A (zh) * 2021-08-18 2023-02-21 丹生医药技术(上海)有限公司 一种TGF-β/VEGF双功能抗体融合蛋白
CA3237245A1 (en) * 2021-11-01 2023-05-04 Genzyme Corporation Treatment of osteogenesis imperfecta
KR20250004747A (ko) 2022-04-13 2025-01-08 이뮤니티바이오, 인크. 생체 시계 유전자 장애의 치료에 사용하기 위한 다중-사슬 키메라 폴리펩티드
KR20250004757A (ko) 2022-04-13 2025-01-08 이뮤니티바이오, 인크. 신경염증성 장애의 치료에 사용하기 위한 다중-사슬 키메라 폴리펩티드
CN115508565B (zh) * 2022-10-20 2024-11-15 成都医学院第一附属医院 Cilp1作为肾纤维化生物标志物的应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
DE69721548T2 (de) 1996-02-09 2004-04-01 Abbott Laboratories(Bermuda)Ltd. HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN
US6455495B1 (en) 1997-02-14 2002-09-24 The Salk Institute For Biological Studies Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
MY131805A (en) 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
EP1074563A1 (en) 1999-08-02 2001-02-07 F. Hoffmann-La Roche Ag Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
US20020063763A1 (en) 2000-11-29 2002-05-30 Mantell David Allen Apparatus and method for removing air bubbles from an ink jet printhead
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
BR0317896A (pt) 2002-12-31 2005-12-06 Altus Pharmaceuticals Inc Complexos de cristais de proteìna e polìmeros iÈnicos
WO2004098637A1 (en) 2003-04-30 2004-11-18 Genzyme Corporation Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
EP1646655A2 (en) 2003-07-09 2006-04-19 Eli Lilly And Company Tgf-beta1 ligands
CA2561686C (en) * 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
HUE055861T2 (hu) 2004-04-21 2021-12-28 Alexion Pharma Inc Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez
PT3520815T (pt) 2005-02-08 2022-02-02 Genzyme Corp Anticorpos contra tgfbeta
TW200714289A (en) 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
WO2008145142A1 (en) 2007-05-31 2008-12-04 Genmab A/S Stable igg4 antibodies
GEP20156390B (en) 2008-01-03 2015-11-10 Scripps Research Inst Antibody targeting through a modular recognition domain
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
EP2927240A1 (en) 2008-08-25 2015-10-07 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
KR101745394B1 (ko) 2008-12-22 2017-06-09 노보 노르디스크 에이/에스 조직 인자 경로 억제자에 대한 항체
EP3141561B1 (en) 2009-04-24 2018-09-12 Vanderbilt University Anti-tgf-beta induction of bone growth
IL300733B1 (en) 2010-03-05 2025-10-01 Univ Johns Hopkins Compositions and methods for antibodies and fusion proteins targeted for immune modulation
KR20160044598A (ko) 2011-03-29 2016-04-25 로슈 글리카트 아게 항체 Fc 변이체
PL2699264T3 (pl) 2011-04-20 2018-08-31 Medimmune, Llc Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1
AU2012261933B2 (en) 2011-06-03 2017-06-15 Xoma Technology Ltd. Antibodies specific for TGF-beta
CN116063522A (zh) 2011-06-13 2023-05-05 美国全心医药生技股份有限公司 抗psgl-1抗体及其用途
SG11201401605QA (en) 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
EP2855527B1 (en) 2012-05-31 2018-08-01 Innate Pharma Tlr3 binding agents
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
EP2908913B1 (en) * 2012-10-17 2018-10-03 Cedars-Sinai Medical Center Molecular signatures of ovarian cancer
PL3312195T3 (pl) * 2013-03-20 2020-04-30 Genzyme Corporation Sposoby leczenia wrodzonej łamliwości kości
CA2911514A1 (en) 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation
ES2792183T3 (es) 2013-09-13 2020-11-10 Beigene Switzerland Gmbh Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
KR102630750B1 (ko) * 2013-12-17 2024-01-30 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
US20170216401A1 (en) 2014-03-17 2017-08-03 Piotr Jachimczak Combination for use in a method of treating cancer
CN107428825A (zh) 2014-10-10 2017-12-01 创祐生技股份有限公司 治疗及/或预防肿瘤生长、侵袭及/或转移的方法
MX389663B (es) 2014-10-14 2025-03-20 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
EP3250250A4 (en) 2015-01-30 2019-05-22 President and Fellows of Harvard College PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY
TWI733661B (zh) * 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
JP6901400B2 (ja) 2015-04-03 2021-07-14 ゾーマ テクノロジー リミテッド ＴＧＦ−β及びＰＤ−１の阻害物質を使用する癌の治療法
NZ735820A (en) 2015-04-17 2025-02-28 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
WO2017011773A2 (en) 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
EP3344660B1 (en) 2015-08-31 2025-03-05 National Research Council of Canada Tgf-beta-receptor ectodomain fusion molecules and uses thereof
CA3033614A1 (en) 2016-08-11 2018-02-15 Precithera, Inc. Tgf-.beta. antagonist conjugates
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
AR110755A1 (es) 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso

Also Published As

Publication number Publication date
CN117417939A (zh) 2024-01-19
CA3050845A1 (en) 2018-07-26
AU2018209391B2 (en) 2024-08-15
JP7411832B2 (ja) 2024-01-11
US12049496B2 (en) 2024-07-30
CN110520441B (zh) 2023-11-14
AU2018209391A1 (en) 2019-09-05
JP2023052376A (ja) 2023-04-11
IL268112A (en) 2019-09-26
CN117417939A8 (zh) 2024-07-12
JP7213186B2 (ja) 2023-01-26
CN110520441B8 (zh) 2024-07-09
IL268112B2 (en) 2025-09-01
MY200751A (en) 2024-01-13
US20250026821A1 (en) 2025-01-23
US20200399358A1 (en) 2020-12-24
MX2023002588A (es) 2023-03-22
AU2024264593A1 (en) 2024-12-05
NZ756431A (en) 2025-03-28
IL323799A (en) 2025-12-01
BR112019014787A2 (pt) 2020-02-27
US11242384B2 (en) 2022-02-08
US20220195026A1 (en) 2022-06-23
US10766955B2 (en) 2020-09-08
TWI787230B (zh) 2022-12-21
CR20190375A (es) 2019-12-17
CO2019008946A2 (es) 2019-09-30
ECSP19059553A (es) 2019-08-30
TW201833135A (zh) 2018-09-16
IL311866B1 (en) 2025-11-01
DOP2019000191A (es) 2019-10-15
IL268112B1 (en) 2025-05-01
JP2020514310A (ja) 2020-05-21
MA47311A (fr) 2019-11-27
TW202313678A (zh) 2023-04-01
IL311866A (en) 2024-06-01
TWI856437B (zh) 2024-09-21
PH12019501635A1 (en) 2019-11-04
SG11201906660TA (en) 2019-08-27
JP2024038040A (ja) 2024-03-19
ZA201904494B (en) 2020-12-23
CL2019002011A1 (es) 2019-11-22
PE20200734A1 (es) 2020-07-23
CN110520441A (zh) 2019-11-29
US20180244763A1 (en) 2018-08-30
MX2019008551A (es) 2020-01-27
UY37575A (es) 2018-10-31

Similar Documents

Publication Publication Date Title
US12049496B2 (en) Anti-TGF-beta antibodies and their use
JP7523084B2 (ja) 抗ガレクチン－９抗体及びその使用
EP3571227A1 (en) Anti-tgf-beta antibodies and their use
JP2019513008A (ja) Ｂｔｌａに対して特異性を有する抗体及びその使用
CN109476748A (zh) 用于癌症的治疗和诊断方法
US20220378909A1 (en) Methods of Treating Cancer with Anti-PD-1 Antibodies
KR102699080B1 (ko) 항-tgf-베타 항체 및 이의 용도
EA049204B1 (ru) Антитела к tgf-бета и их применение
EA041300B1 (ru) Антитела к tgf-бета и их применение
NZ796440A (en) Anti-TGF-beta antibodies and their use